Quantcast

JDP Therapeutics Announces Notice of Allowance for U.S. Patent Covering JDP-205

July 17, 2012

JDP Therapeutics Inc., a privately held clinical stage specialty pharmaceutical company, today announced that the United States Patent and Trademark Office (USPTO) has allowed a new patent that covers JDP´s lead product JDP-205

Blue Bell, Pennsylvania (PRWEB) July 17, 2012

JDP Therapeutics Inc., a privately held clinical stage specialty pharmaceutical company, announced that the United States Patent and Trademark Office (USPTO) has allowed a new patent that covers JDP´s lead product JDP-205, further expanding the intellectual property portfolio for the company’s lead asset, which is currently starting in Phase II clinical trials. This Notice of Allowance is for JDP´s Patent Application Serial Number 12/704,089, titled “Non-sedating Antihistamine Injection Formulation and Method of Use thereof”. The allowed patent claims a new method of use of JDP´s lead product JDP-205 for the treatment of acute allergic reactions. This newly allowed patent will protect JDP-205, with its patent coverage term, through year 2030.

“The grant of the Notice of Allowance is a great milestone for us”, stated Dr. Jie Du, Chief Executive Officer of JDP, “This patent is part of the company´s expanding IP portfolio covering JDP-205 and JDP-207. The company is currently prosecuting 9 pending U.S. and international patent applications to protect the commercial potential of JDP-205 and JDP-207 to year 2030 and beyond.”

About JDP-205

JDP-205 is a proprietary injectable product being developed for the treatment of acute allergic reactions for the hospital market. A survey of 110 physicians revealed that 86% of responding doctors had indicated readiness to use JDP-205 in place of the current therapy when the product is approved by the FDA. A second independent study with in-depth clinician interviews confirmed the findings.

Acute allergic reaction is a serious condition, potentially life-threatening, and has been growing at concerning rates with very limited selections of medications for treatment. JDP-205 will offer an alternative and superior treatment to the current therapy for the first time in nearly 60 years.

About JDP-207

JDP-207 is a proprietary drug product, and a first-in-class therapy being developed for the treatment of acute allergic reactions for patients´ self-administration. Acute allergic reaction is a serious condition, potentially life-threatening, and has been growing at an alarming rate in the last two decades due to increased human exposure to ever growing varieties of food and pharmaceuticals. Currently there are very limited selections of medications for treatment. JDP-207 will offer a new method and a superior treatment regimen for patients suffering from acute allergic reactions.

About JDP Therapeutics Inc.

JDP Therapeutics Inc. is a privately held, clinical stage specialty pharmaceutical company focused on developing small molecule therapeutics to treat life threatening diseases with significant unmet medical needs, primarily for use of acute care in the hospital setting.

JDP Therapeutics pursues unfulfilled opportunities in existing molecules from which it develops unique dosage forms, novel formulations, and new indications to achieve full therapeutic and market potential. This approach mitigates risk, shortens the development cycle, leads to a well-defined regulatory pathway, and fully characterizes clinical needs for each product opportunity.

For further information, please email info(at)jdptherapeutics(dot)com

###

Safe Harbor Statement Regarding Forward-looking Statements

The statements in this release and oral statements made by representatives of JDP relating to matters that are not historical facts, including without limitation those regarding the timing or potential outcomes of research or clinical trials, any market that might develop for any of JDP´s product candidates are forward-looking statements that involve risks and uncertainties.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/7/prweb9695617.htm


Source: prweb



comments powered by Disqus